A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin.
D020155:3-Hydroxybutyric Acid; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005934:Glucagon / Q000097:blood; D005990:Glycerol / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006885:Hydroxybutyrates / Q000097:blood; D007003:Hypoglycemia / Q000097:blood; D007328:Insulin / Q000097:blood; D007332:Insulin Infusion Systems; D008297:Male; D008875:Middle Aged; D013004:Somatostatin / Q000627:therapeutic use*
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D007328:Insulin; D013004:Somatostatin; D013006:Growth Hormone; D005934:Glucagon; D005990:Glycerol; D020155:3-Hydroxybutyric Acid; D006854:Hydrocortisone